{"gene":"CSPG4","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2021,"finding":"Cryo-EM structure of TcdB-CSPG4 complex revealed that CSPG4 is a receptor for C. difficile toxin TcdB, with a unique binding site composed of multiple discontinuous regions across TcdB. CSPG4-knockout mice showed reduced colonic tissue damage during C. difficile infections, and mutations selectively disrupting CSPG4 binding reduced TcdB toxicity in mice. Bezlotoxumab blocks CSPG4 binding to TcdB via an allosteric mechanism.","method":"Cryo-EM structure determination, site-directed mutagenesis, CSPG4-knockout mouse model, in vivo toxicity assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure with functional mutagenesis validation and in vivo KO model, multiple orthogonal methods in single study","pmids":["34145250"],"is_preprint":false},{"year":2017,"finding":"The CSPG4-binding site on TcdB maps to a region at the junction of the translocation and CROP domains, requiring at least three CROP short repeats for binding and full toxicity on CSPG4-expressing cells. The anti-TcdB antibody bezlotoxumab prevents CSPG4 binding by overlapping with the CSPG4-binding site in the first three short repeats.","method":"C-terminal truncation series, receptor-binding mutant screen, cell intoxication assays, competitive binding assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic mutagenesis with multiple truncation constructs and functional validation, single lab but orthogonal methods","pmids":["28842504"],"is_preprint":false},{"year":2024,"finding":"Extracellular Ca2+ promotes preferential TcdB binding to CSPG4 (protein core), while the chondroitin sulfate (CS) moiety of CSPG4 does not enhance Ca2+-mediated binding but instead influences the rate of TcdB cell entry after surface binding.","method":"TcdB receptor-binding mutants, cell lines with varied receptor profiles, Ca2+ manipulation assays, binding and cytotoxicity assays","journal":"mSphere","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-binding mutants and cell-line panel with two orthogonal endpoints (binding vs. entry), single lab","pmids":["38470254"],"is_preprint":false},{"year":2023,"finding":"Nectin-3 and shed forms of CSPG4 (shed by fibroblasts along the crypt-surface axis) serve as epithelial cell receptors for C. difficile TcdB on colonic epithelial cells, with CSPG4 localized at epithelial cell junctions as visualized by immunofluorescence microscopy on colonic tissue.","method":"Immunofluorescence microscopy on colonic tissue sections","journal":"mBio","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct tissue localization experiment revealing receptor access mechanism, single lab, single primary method","pmids":["37747247"],"is_preprint":false},{"year":2018,"finding":"CSPG4 binds to the basement membrane proteoglycan perlecan via hydrophobic protein-protein interactions involving multiple sites on perlecan including the C-terminal region. This CSPG4-perlecan interaction supports cell adhesion and actin polymerization.","method":"Immunopurification of CSPG4 from melanoma cell lines, co-complex formation assay, mechanistic domain-mapping with purified perlecan fragments, actin polymerization assay","journal":"Journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical pulldown with domain-mapping and functional cell adhesion/actin readout, single lab","pmids":["29462330"],"is_preprint":false},{"year":2013,"finding":"NG2/CSPG4 interacts with collagen type VI (Col VI) through reciprocal binding sites identified using dominant-negative NG2 mutants and purified Col VI domain fragments. NG2-Col VI binding triggers activation of PI-3K-dependent cell survival and cell adhesion/migration signaling pathways, controlling sarcoma cell adhesion and motility.","method":"Dominant-negative NG2 mutant cells, purified Col VI domain fragments, RNAi knockdown, ectopic transduction of full-length/deletion NG2 constructs, in vitro adhesion/motility assays, xenograft models","journal":"Journal of molecular cell biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal approaches (domain-deletion mutants, RNAi, ectopic expression, domain-fragment competition) converging on binding sites and PI-3K pathway activation","pmids":["23559515"],"is_preprint":false},{"year":2011,"finding":"CSPG4-specific antibody (scFv-FcC21) inhibits tumor cell growth and migration by blocking activation of ERK (required for growth) and focal adhesion kinase (FAK) signaling (required for migration) in CSPG4-positive tumor cells.","method":"Phage display antibody generation, in vitro growth and migration assays, signaling pathway analysis (ERK and FAK phosphorylation), in vivo xenograft tumor growth assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function via antibody blockade with defined signaling readouts and in vivo confirmation, single lab","pmids":["22021902"],"is_preprint":false},{"year":2010,"finding":"CSPG4-specific mAb 225.28 inhibits TNBC cell growth, adhesion, and migration in vitro, with antitumor mechanisms including increased apoptosis, reduced mitotic activity, decreased tumor vascularity, and reduced activation of survival/proliferation/metastasis signaling pathways.","method":"In vitro growth, adhesion, and migration assays; apoptosis assays; in vivo metastasis and orthotopic xenograft models; signaling pathway analysis","journal":"Journal of the National Cancer Institute","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vitro and in vivo endpoints with mechanistic pathway readouts, single lab","pmids":["20852124"],"is_preprint":false},{"year":2012,"finding":"CSPG4 mediates mesothelioma cell adhesion via engagement of extracellular matrix (ECM); mAb TP41.2 blockade of CSPG4 decreases phosphorylation of FAK and AKT, reduces cyclin D1 expression, and induces apoptosis, establishing CSPG4 as a key upstream regulator of FAK/AKT/cyclin D1 signaling in mesothelioma.","method":"CSPG4 antibody blockade, adhesion assays, immunoblotting for FAK and AKT phosphorylation, cyclin D1 expression, apoptosis assays, in vivo SCID mouse xenograft","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody-mediated loss-of-function with mechanistic signaling readouts, in vitro and in vivo confirmation, single lab","pmids":["22893632"],"is_preprint":false},{"year":2011,"finding":"NG2/CSPG4 overexpression in GBM cells increases tumor growth rate, angiogenesis, and vascular permeability in vivo. NG2 knockdown (via lentiviral shRNA) in patient-derived GBM xenografts and melanoma tumors reduced tumor growth, oedema, and angiogenesis, and normalized vascular function while increasing invasion.","method":"NG2-overexpressing GBM xenografts, lentiviral shRNA knockdown in intracranial patient GBM xenografts and subcutaneous melanoma tumors, tumor growth measurements, vascular permeability and angiogenesis assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function in vivo models with multiple orthogonal phenotypic readouts, single lab","pmids":["21829586"],"is_preprint":false},{"year":2017,"finding":"NG2/CSPG4 knockdown in established soft-tissue sarcoma cells decreased tumor volume by ~two-thirds and cell proliferation by 50%; NG2/CSPG4 deletion at tumor initiation paradoxically produced larger tumors associated with downregulation of insulin-like growth factor binding protein (Igfbp) genes, indicating stage-dependent and divergent roles for NG2/CSPG4 in sarcoma.","method":"shRNA knockdown in human sarcoma xenografts, autochthonous mouse sarcoma model with conditional Ng2/Cspg4 deletion, NG2 antibody immunotherapy, gene expression profiling","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple complementary models (KD, KO, antibody) with mechanistic gene expression data, single lab","pmids":["29196603"],"is_preprint":false},{"year":2019,"finding":"Furanodienone (FUR) suppresses CSPG4 expression in temozolomide-resistant GBM cells by inhibiting EGR1-dependent transcription of CSPG4, thereby downregulating CSPG4-Akt-ERK signaling, suppressing inflammatory responses, and activating caspase-dependent apoptosis.","method":"In vitro cytotoxicity assays, immunofluorescence, dual-luciferase reporter assay for EGR1-mediated CSPG4 transcription, western blotting for pathway components","journal":"Phytotherapy research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — luciferase reporter and pathway analysis establish EGR1-CSPG4 transcriptional link with functional downstream signaling, single lab","pmids":["31006910"],"is_preprint":false},{"year":2023,"finding":"Hippo signaling pathway regulates CSPG4 expression: TcdB-resistant HeLa cells that lost CSPG4 mRNA showed correlated changes in Hippo and estrogen signaling pathways. CRISPR-mediated deletion of key Hippo transcriptional regulators and chemical modulation altered CSPG4 expression. Pharmacological inactivation of Hippo (XMU-MP-1) protected mice from C. difficile disease.","method":"TcdB-resistance selection, mRNA expression profiling, integrated pathway analysis, CRISPR deletion of Hippo pathway regulators, chemical modulation, mouse C. difficile disease model","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR, chemical modulation, and in vivo validation provide multiple orthogonal lines of evidence for Hippo regulation of CSPG4, single lab","pmids":["36972308"],"is_preprint":false},{"year":2021,"finding":"NG2/CSPG4 expression in smooth muscle cells is regulated by myocardin-related transcription factors (MRTFs: MYOCD, MRTF-A/MKL1, MRTF-B/MKL2) acting through serum response factor (SRF). MRTF overexpression increased CSPG4 mRNA and protein; SRF silencing reduced CSPG4 transcript levels; CSPG4 responded to MRTF-SRF inhibitor CCG-1423 and to actin dynamics.","method":"Bioinformatics correlation, MRTF overexpression in human smooth muscle cells, SRF silencing, promoter reporter assays, pharmacological inhibition with CCG-1423","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with transcriptional reporter assays and pharmacological validation, single lab","pmids":["33727640"],"is_preprint":false},{"year":2021,"finding":"The cytosolic isoform of Glutaredoxin 2 (Grx2c) regulates the redox state of transcription factor SP-1, modulating its binding affinity to both the promoter and an enhancer region of the CSPG4 gene, thereby increasing NG2 expression and promoting migration of NG2 glia and invasion of glioma cells.","method":"In vitro human cell lines, ex vivo mouse primary cells, in vivo zebrafish models, glioblastoma patient tissue samples, SP-1 redox state and DNA-binding analysis","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple model systems (in vitro, ex vivo, in vivo) and mechanistic link from Grx2c redox to SP-1 binding to CSPG4 transcription, single lab","pmids":["34952462"],"is_preprint":false},{"year":2018,"finding":"A 1.45 kb intronic enhancer of the mouse Cspg4 gene directs transcription to NG2 glia but not pericytes in vitro and in transgenic mice. This enhancer contains binding sites for SoxE and basic helix-loop-helix (bHLH) transcription factors, whose cooperative binding augments enhancer activity; mutations in these binding elements abolished enhancer activity.","method":"In vitro enhancer assays, EGFP reporter transgenic mice, site-directed mutagenesis of transcription factor binding elements","journal":"Glia","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reporter + transgenic in vivo validation + mutagenesis of binding elements, multiple orthogonal methods, single lab","pmids":["30306660"],"is_preprint":false},{"year":2018,"finding":"APEX2-FGF1 proximity labeling identified CSPG4 (NG2) and CD44 as novel FGF1 binding partners at the cell surface. CSPG4 and FGF1 colocalize at the cell surface, suggesting CSPG4 acts as a storage molecule creating a reservoir of FGF1 at the cell surface.","method":"APEX2-FGF1 fusion protein proximity biotin labeling, mass spectrometry identification, co-localization imaging, signaling assay for functional validation","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proximity labeling with MS identification and colocalization confirmation, single lab, novel interaction","pmids":["29812912"],"is_preprint":false},{"year":2013,"finding":"CSPG4 siRNA knockdown in human extravillous trophoblast (EVT) cells stimulated proliferation and decreased migration/invasion, demonstrating that CSPG4 promotes trophoblast migration and invasion. IL11 and LIF cytokines stimulated CSPG4 mRNA and protein expression in first-trimester placental villous explants.","method":"siRNA knockdown in HTR8/SVneo cells, proliferation and migration/invasion assays, cytokine stimulation of placental villous explants","journal":"Placenta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA loss-of-function with defined cellular phenotype readouts and cytokine regulation, single lab","pmids":["23953863"],"is_preprint":false},{"year":2023,"finding":"Trophoblast-specific CSPG4 knockdown in mice caused frequent fetal loss and poor placentation, with reduced placental weight. CSPG4-knockout trophoblast cells showed inhibited proliferation and invasion, with reduced AKT and ERK phosphorylation and decreased MMP2 and MMP9 expression.","method":"Trophoblast-specific lentiviral CSPG4 knockdown mouse model, CSPG4-knockout trophoblast cell line, proliferation and invasion assays, western blotting for AKT/ERK phosphorylation and MMP expression","journal":"Reproductive biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KD mouse model with cellular mechanistic validation (KO cell line + signaling), single lab","pmids":["36634519"],"is_preprint":false},{"year":2024,"finding":"Chondroitin sulfate (CS) modification on CSPG4 is required for glioma-initiating cell (GIC) maintenance. CS degradation on CSPG4 by ChondroitinaseABC induced GIC differentiation (inhibited by exogenous CS addition). During GIC differentiation, de-CS-modified CSPG4 (lacking CS chains) interacts with integrin αV, activating integrin-ERK signaling that promotes differentiation; CS-modified CSPG4 does not interact with integrin αV.","method":"ChondroitinaseABC treatment, XYLT1 knockdown, CSPG4 knockdown, co-immunoprecipitation of CSPG4 with integrin αV, cyclic-RGD inhibitor assays, proteo-genomics of patient-derived GIC clones","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — enzymatic modification, genetic knockdown, co-IP, and pharmacological inhibition all converging on CS-CSPG4–integrin αV axis, single lab with multiple orthogonal methods","pmids":["38309500"],"is_preprint":false},{"year":2022,"finding":"NG2/CSPG4 is required for mechanical activation of ERK 1/2 in TMJ cartilage cells; NG2/CSPG4 knockout mice have more severe cartilage degeneration during TMJ osteoarthritis, elevated OA proteases, and suppressed OA matrix synthesis genes. In vitro, NG2/CSPG4 KO cells fail to mechanically activate ERK 1/2 under compression loading.","method":"Surgical destabilization-induced TMJ OA in NG2/CSPG4 KO mice, transcriptome and protein analysis, compression bioreactor on cell-agarose-collagen scaffolds, ERK 1/2 phosphorylation assays","journal":"Frontiers in dental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO model combined with in vitro mechanobiological assay, multiple readouts, single lab","pmids":["36685663"],"is_preprint":false},{"year":2021,"finding":"Myelin debris from damaged myelin sheaths increases NG2/CSPG4 expression in bone marrow-derived macrophages (BMDMΦ) after spinal cord injury, and these NG2/CSPG4-expressing macrophages exhibit enhanced proliferation and decreased phagocytic capacity.","method":"Spinal cord injury mouse model, identification of BMDMΦ as NG2/CSPG4 source, myelin debris stimulation in vitro with functional assays (proliferation, phagocytosis)","journal":"Frontiers in cellular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo SCI model combined with in vitro mechanistic stimulation and functional readouts, single lab","pmids":["33815067"],"is_preprint":false},{"year":2016,"finding":"shRNA knockdown of CSPG4/NG2 in the JJ012 chondrosarcoma cell line reduced cell proliferation and migration, decreased gene expression of MMP3 and ADAMTS4 proteases, and increased sensitivity to doxorubicin.","method":"Stable shRNA knockdown, cell proliferation and migration assays, gene expression analysis of MMP3 and ADAMTS4, doxorubicin sensitivity assay","journal":"International journal of experimental pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — stable KD with multiple functional readouts, single lab, single cell line","pmids":["27292772"],"is_preprint":false},{"year":2016,"finding":"Using lineage tracing in mice, bone and soft-tissue sarcomas (driven by Trp53 deletion) and desmoid tumors (driven by Apc mutation) can originate from Ng2/Cspg4-expressing pericytes. β-catenin stabilization in Ng2/Cspg4+ cells caused desmoid tumors, while Trp53 deletion caused sarcomas. β-catenin signaling was inhibited in sarcomas versus precursor pericytes, and β-catenin activation inhibited sarcoma formation and growth.","method":"Cre-based lineage tracing from Ng2/Cspg4-expressing cells, conditional Trp53 deletion and Apc mutation mouse models, gene expression profiling, β-catenin activation experiments","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic lineage tracing with conditional oncogene models and mechanistic β-catenin pathway validation, multiple orthogonal approaches, single lab","pmids":["27425618"],"is_preprint":false},{"year":2021,"finding":"BRAF and MEK inhibitor treatment of BRAF-mutant melanoma cells results in markedly reduced CSPG4 protein and mRNA levels (not via increased shedding). Patient-derived matched tumor samples following kinase inhibitor therapy showed decreased numbers of CSPG4-positive cells compared to pre-therapy samples.","method":"Flow cytometry, immunofluorescence, western blotting, qPCR, measurement of CSPG4 in culture supernatants, patient tumor sample IHC","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple protein and mRNA assays plus patient sample validation linking BRAF/MEK signaling to CSPG4 expression regulation, single lab","pmids":["33649790"],"is_preprint":false},{"year":2018,"finding":"iPSC-derived oligodendrocyte precursor cells (OPCs) from carriers of the CSPG4-A131T missense mutation exhibited abnormal post-translational processing and subcellular localization of mutant NG2/CSPG4, aberrant cellular morphology, reduced viability, and impaired myelination potential. Transfection of healthy OPCs with either CSPG4-A131T or CSPG4-V901G mutants confirmed pathogenic effects on cell survival.","method":"iPSC-derived OPCs from mutation carriers, protein processing/localization assays, morphology quantification, viability assays, myelination assay, transfection of healthy OPCs with mutant constructs, in vivo diffusion tensor imaging","journal":"Molecular psychiatry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient-derived iPSC model with multiple cellular phenotype readouts and confirmation by transfection in healthy cells, single lab","pmids":["29302076"],"is_preprint":false},{"year":2025,"finding":"NLGN3 (neuroligin-3) shed by neurons interacts directly with CSPG4 on glioma cells and oligodendrocyte precursor cells (OPCs), facilitating CSPG4 shedding by ADAM10. This NLGN3-CSPG4 interaction and consequent shedding alter membrane tension, activating PIEZO1 mechanosensitive channels and causing membrane depolarization, maintaining OPCs in an undifferentiated state and promoting glioma proliferation.","method":"Biochemical interaction assays (NLGN3-CSPG4 binding), ADAM10 shedding assays, PIEZO1 channel activity measurements, membrane tension assays, glioma proliferation assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — preprint describing novel molecular pathway with biochemical interaction and functional validation but not yet peer reviewed, single lab","pmids":["40791371"],"is_preprint":true},{"year":2021,"finding":"Cspg4-expressing microglia represent a specific proliferative subset during neurodegeneration. Their transcriptomic signature is enriched for cell cycle genes and depleted for neuroinflammation/phagocytosis genes. Pathological α-synuclein evokes proliferation of quiescent Cspg4 microglia. Cspg4 microglia grafts show higher survival than Cspg4-negative microglia upon transplantation into adult brain with depleted endogenous microglia.","method":"Transcriptomic profiling of Cspg4 microglia subsets, PD mouse models, pathological α-synuclein stimulation, microglia transplantation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptomics plus functional in vivo transplantation and α-synuclein stimulation experiments, single lab","pmids":["36795751"],"is_preprint":false},{"year":2024,"finding":"Zebrafish lacking cspg4 function produce normal numbers of oligodendrocyte lineage cells that undergo proper differentiation and produce myelin sheaths of normal number and length, but OPC morphology is aberrant in mutant larvae, establishing that Cspg4 specifically regulates OPC morphogenesis but is not required for OLC differentiation or myelination.","method":"cspg4 loss-of-function zebrafish model, OPC morphology quantification, OLC differentiation assessment, myelin sheath number and length measurement","journal":"Differentiation; research in biological diversity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic KO in vivo with multiple orthogonal readouts distinguishing morphogenesis from differentiation/myelination, single lab","pmids":["39566199"],"is_preprint":false},{"year":2025,"finding":"CSPG4 expressed on mesenchymal progenitor cells (MPCs) promotes vascular endothelial cell migration; CSPG4 KO in MPCs abrogated upregulation of endothelial migration. In CSPG4 KO rats, skeletal muscle development was perturbed with impaired angiogenesis, and muscle regeneration showed reduced CD31-positive cells at regenerating sites.","method":"CSPG4 KO rat model, muscle regeneration assay, co-culture of CSPG4-expressing vs KO MPCs with endothelial cells, endothelial cell migration assay, CD31 immunostaining","journal":"Animal science journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO rat model combined with in vitro co-culture mechanistic assay, multiple readouts, single lab","pmids":["40769519"],"is_preprint":false},{"year":2021,"finding":"CSPG4 silencing in choroid plexus cells suppressed ferroptosis, cell adhesion function, and intracellular Ca2+ flow in a post-hemorrhagic hydrocephalus (PHH) model, suggesting CSPG4 participates in ferroptosis and Ca2+ signaling relevant to PHH pathophysiology.","method":"CSPG4 silencing in vitro cellular experiments, rat PHH models, ferroptosis assay, cell adhesion assay, intracellular Ca2+ flow measurement","journal":"Advanced science","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, KD with functional readouts but mechanistic pathway placement preliminary, choroid plexus context not well established for CSPG4","pmids":["39686677"],"is_preprint":false},{"year":2021,"finding":"CSPG4 expression during decidualization is required for trophoblast invasion: CSPG4 knockdown in endometrial stromal cells inhibited decidualization and subsequently inhibited trophoblast invasion. CSPG4 expression increases during artificially induced decidualization in both human cells and mouse models.","method":"siRNA knockdown of CSPG4 in endometrial stromal cells, decidualization induction assay, trophoblast invasion assay, qPCR and western blotting in pseudopregnant and pregnant mouse endometria","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — siRNA KD with downstream trophoblast invasion assay and in vivo mouse validation, single lab","pmids":["39563514"],"is_preprint":false},{"year":2021,"finding":"A germline V2097M variant in CSPG4 promoted cell proliferation by activating the MAPK/ERK signaling pathway via hindering ectodomain cleavage of CSPG4, as demonstrated by in vitro functional studies.","method":"Targeted sequencing, whole-exome sequencing, in vitro functional cell proliferation assays, MAPK/ERK signaling analysis, ectodomain cleavage assay","journal":"Cell death & disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single variant, in vitro with limited mechanistic detail in abstract about how cleavage hindering is established","pmids":["34344877"],"is_preprint":false},{"year":2022,"finding":"BLR (linarin derivative) increased CSPG4 gene expression and enhanced CSPG4 membrane localization, with downstream signaling protein expression associated with KDEL receptor (KDELR) activation; activated KDELR further increased phosphorylation of MAPKs. CSPG4 upregulation correlated with increased cerebral blood flow and protection from ischemic brain injury.","method":"Mouse MCAO model, RNA sequencing, coimmunoprecipitation, western blotting, laser speckle contrast imaging","journal":"Oxidative medicine and cellular longevity","confidence":"Low","confidence_rationale":"Tier 3 / Weak — co-IP and gene expression data with in vivo model, but mechanistic link between KDELR-CSPG4 interaction and downstream MAPK is incompletely established from abstract alone, single lab","pmids":["35927993"],"is_preprint":false}],"current_model":"CSPG4 (NG2/HMW-MAA) is a large transmembrane chondroitin sulfate proteoglycan that functions as a multi-functional cell surface scaffold: it acts as a primary receptor for C. difficile TcdB toxin (binding via the toxin's CROP domain in a Ca2+-dependent manner, with its CS chains facilitating cell entry); it engages extracellular matrix ligands including collagen type VI and perlecan to promote cell adhesion and motility via PI-3K and FAK signaling; it modulates growth factor receptor (RTK) and integrin signaling to sustain ERK1/2 and AKT activation supporting tumor cell proliferation, survival, and angiogenesis; its CS modification controls interactions with integrin αV to regulate glioma stem cell maintenance versus differentiation; it interacts with shed NLGN3 to activate ADAM10-mediated shedding and PIEZO1 mechanosensitive channel signaling in glial precursors; its transcription is regulated by SoxE/bHLH factors (via an intronic enhancer), MRTF-SRF, SP-1 (redox-regulated by Grx2c), EGR1, and the Hippo pathway; and loss-of-function studies establish roles in OPC morphogenesis, trophoblast invasion, angiogenesis during muscle regeneration, and cartilage mechanical homeostasis via ERK1/2."},"narrative":{"mechanistic_narrative":"CSPG4 (NG2/HMW-MAA) is a large transmembrane chondroitin sulfate proteoglycan that functions as a multifunctional cell-surface scaffold coupling extracellular matrix and growth-factor cues to intracellular survival, proliferation, and motility signaling [PMID:23559515, PMID:38309500]. It serves as a host receptor for Clostridioides difficile toxin TcdB: the binding interface maps to discontinuous regions spanning the junction of the toxin's translocation and CROP domains, requires at least three CROP short repeats, is potentiated by extracellular Ca2+ acting on the CSPG4 protein core, and is blocked by the therapeutic antibody bezlotoxumab; CSPG4-knockout mice are protected from colonic damage, and the chondroitin sulfate (CS) chains accelerate toxin cell entry after surface binding [PMID:34145250, PMID:28842504, PMID:38470254]. In epithelial tissue, junctional and fibroblast-shed CSPG4 provides receptor access along the colonic crypt-surface axis [PMID:37747247]. As an adhesion and signaling receptor, CSPG4 engages matrix ligands including collagen type VI and the basement-membrane proteoglycan perlecan to drive actin polymerization, adhesion, and motility through PI-3K and FAK signaling [PMID:29462330, PMID:23559515], and sustains FAK/AKT/ERK and cyclin D1 signaling that supports tumor cell proliferation, survival, migration, and angiogenesis across melanoma, mesothelioma, sarcoma, and glioma [PMID:22021902, PMID:22893632, PMID:21829586]. Its CS modification acts as a molecular switch: CS-bearing CSPG4 maintains glioma-initiating cells, whereas CS removal permits CSPG4 binding to integrin αV and activation of integrin-ERK signaling that promotes differentiation [PMID:38309500]. CSPG4 abundance is set transcriptionally by SoxE/bHLH factors acting through an NG2-glia-specific intronic enhancer, by MRTF-SRF, by redox-regulated SP-1, by EGR1, and by Hippo signaling [PMID:30306660, PMID:33727640, PMID:34952462, PMID:31006910, PMID:36972308]. Loss-of-function studies establish physiological roles in OPC morphogenesis, trophoblast invasion and placentation, angiogenesis during muscle regeneration, and cartilage mechanical homeostasis via mechanically activated ERK1/2 [PMID:39566199, PMID:36634519, PMID:40769519, PMID:36685663]. A germline CSPG4-A131T missense mutation in iPSC-derived oligodendrocyte precursors causes aberrant protein processing, mislocalization, abnormal morphology, and impaired myelination potential, linking CSPG4 dysfunction to disease [PMID:29302076].","teleology":[{"year":2013,"claim":"Established that CSPG4 is not merely a passive matrix component but an adhesion receptor that transduces matrix engagement into survival and motility signaling, defining its mechanistic role in tumor cells.","evidence":"Domain-deletion and dominant-negative NG2 mutants, purified collagen VI fragments, RNAi, and xenografts mapping NG2-Col VI binding to PI-3K activation","pmids":["23559515"],"confidence":"High","gaps":["Did not define the membrane-proximal signaling complex linking CSPG4 to PI-3K","Generality beyond sarcoma not established in this study"]},{"year":2018,"claim":"Resolved how CSPG4 transcription is restricted to NG2 glia versus pericytes, identifying the cis-regulatory logic that establishes cell-type-specific expression.","evidence":"1.45 kb intronic enhancer reporter assays, EGFP transgenic mice, and mutagenesis of SoxE/bHLH binding elements","pmids":["30306660"],"confidence":"High","gaps":["Did not identify the specific SoxE/bHLH family members in vivo","Did not address how pericyte CSPG4 is driven"]},{"year":2018,"claim":"Extended CSPG4's ligand repertoire to perlecan and to FGF1, framing it as a surface reservoir for matrix and growth-factor ligands.","evidence":"Immunopurification with perlecan domain-mapping and actin assays; APEX2-FGF1 proximity labeling with mass spectrometry and colocalization","pmids":["29462330","29812912"],"confidence":"Medium","gaps":["FGF1 storage function not functionally proven downstream","Whether perlecan and FGF1 binding involve overlapping CSPG4 regions unknown"]},{"year":2021,"claim":"Solved the structural basis of CSPG4 as the TcdB receptor and validated it in vivo, transforming a cell-surface marker into a defined toxin-host interface with therapeutic relevance.","evidence":"Cryo-EM of the TcdB-CSPG4 complex, site-directed mutagenesis disrupting binding, CSPG4-knockout mice, and bezlotoxumab competition","pmids":["34145250","28842504"],"confidence":"High","gaps":["Did not resolve the CS contribution to entry kinetics","Relative in vivo contribution versus other TcdB receptors unquantified"]},{"year":2021,"claim":"Defined multiple transcriptional inputs (MRTF-SRF, redox-regulated SP-1) that tune CSPG4 abundance in smooth muscle and glia, connecting actin dynamics and cellular redox state to receptor expression.","evidence":"MRTF overexpression and SRF silencing with promoter reporters and CCG-1423; Grx2c manipulation with SP-1 redox/DNA-binding analysis across cell, ex vivo, and zebrafish models","pmids":["33727640","34952462"],"confidence":"Medium","gaps":["Cross-talk between MRTF-SRF and SP-1 inputs not integrated","Direct redox modification site on SP-1 controlling CSPG4 not mapped"]},{"year":2023,"claim":"Connected receptor access and expression control in vivo, showing fibroblast-shed CSPG4 and Hippo-dependent transcription govern epithelial susceptibility to TcdB.","evidence":"Immunofluorescence of colonic crypt-surface axis; TcdB-resistance selection, CRISPR deletion of Hippo regulators, chemical modulation, and mouse disease protection","pmids":["37747247","36972308"],"confidence":"Medium","gaps":["Identity of the protease shedding epithelial CSPG4 not defined","Direct Hippo transcriptional regulators binding the CSPG4 locus not mapped"]},{"year":2024,"claim":"Showed that the chondroitin sulfate modification acts as a binary switch controlling CSPG4 partner choice, with de-CS-modified CSPG4 binding integrin αV to drive differentiation versus CS-bearing CSPG4 maintaining stem-like state.","evidence":"ChondroitinaseABC and XYLT1/CSPG4 knockdown, co-IP with integrin αV, cyclic-RGD inhibition, and proteo-genomics of patient-derived glioma-initiating cells","pmids":["38309500"],"confidence":"High","gaps":["Enzyme/signal controlling CS removal physiologically not identified","Whether this switch operates in non-glioma contexts unknown"]},{"year":2024,"claim":"Genetically isolated a specific physiological function of CSPG4, distinguishing OPC morphogenesis from differentiation and myelination.","evidence":"cspg4 loss-of-function zebrafish with morphology, differentiation, and myelin sheath quantification","pmids":["39566199"],"confidence":"Medium","gaps":["Molecular effector of morphogenesis downstream of CSPG4 not defined","Mammalian conservation of this restricted phenotype untested"]},{"year":2025,"claim":"Proposed a mechanotransduction mechanism whereby neuronal NLGN3 binds CSPG4 and triggers ADAM10 shedding, altering membrane tension to activate PIEZO1 and maintain undifferentiated, proliferative states.","evidence":"Biochemical NLGN3-CSPG4 binding, ADAM10 shedding, PIEZO1 channel and membrane-tension measurements, glioma proliferation assays (preprint)","pmids":["40791371"],"confidence":"Medium","gaps":["Preprint, not yet peer reviewed","Direct causal chain from shedding to PIEZO1 activation not fully reconstituted","In vivo requirement untested"]},{"year":null,"claim":"How CSPG4's diverse inputs—CS-state, matrix ligands, growth factors, and mechanical force—are integrated at the cytoplasmic tail into a unified signaling output remains undefined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No defined cytoplasmic signaling complex linking CSPG4 to ERK/AKT","No structural model of the full-length receptor with its CS chains","Quantitative hierarchy among transcriptional regulators in any single cell type unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[4,5,8]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[5,6,8,19]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[4]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[16]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,3,16,19]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,6,8,19]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[4,5]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[15,13,14,11,12]}],"complexes":[],"partners":["TCDB","COL6","HSPG2","ITGAV","FGF1","NLGN3","ADAM10"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q6UVK1","full_name":"Chondroitin sulfate proteoglycan 4","aliases":["Chondroitin sulfate proteoglycan NG2","Melanoma chondroitin sulfate proteoglycan","Melanoma-associated chondroitin sulfate proteoglycan"],"length_aa":2322,"mass_kda":250.5,"function":"Proteoglycan playing a role in cell proliferation and migration which stimulates endothelial cells motility during microvascular morphogenesis. May also inhibit neurite outgrowth and growth cone collapse during axon regeneration. Cell surface receptor for collagen alpha 2(VI) which may confer cells ability to migrate on that substrate. Binds through its extracellular N-terminus growth factors, extracellular matrix proteases modulating their activity. May regulate MPP16-dependent degradation and invasion of type I collagen participating in melanoma cells invasion properties. May modulate the plasminogen system by enhancing plasminogen activation and inhibiting angiostatin. Also functions as a signal transducing protein by binding through its cytoplasmic C-terminus scaffolding and signaling proteins. May promote retraction fiber formation and cell polarization through Rho GTPase activation. May stimulate alpha-4, beta-1 integrin-mediated adhesion and spreading by recruiting and activating a signaling cascade through CDC42, ACK1 and BCAR1. May activate FAK and ERK1/ERK2 signaling cascades","subcellular_location":"Cell membrane; Apical cell membrane; Cell projection, lamellipodium membrane; Cell surface","url":"https://www.uniprot.org/uniprotkb/Q6UVK1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CSPG4","classification":"Not Classified","n_dependent_lines":19,"n_total_lines":1208,"dependency_fraction":0.015728476821192054},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CSPG4","total_profiled":1310},"omim":[{"mim_id":"619066","title":"ZINC FINGER PROTEIN 532; ZNF532","url":"https://www.omim.org/entry/619066"},{"mim_id":"610782","title":"MICRO RNA 29A; MIR29A","url":"https://www.omim.org/entry/610782"},{"mim_id":"606386","title":"OLIGODENDROCYTE LINEAGE TRANSCRIPTION FACTOR 2; OLIG2","url":"https://www.omim.org/entry/606386"},{"mim_id":"605357","title":"STONIN 1; STON1","url":"https://www.omim.org/entry/605357"},{"mim_id":"601172","title":"CHONDROITIN SULFATE PROTEOGLYCAN 4; CSPG4","url":"https://www.omim.org/entry/601172"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":124.5}],"url":"https://www.proteinatlas.org/search/CSPG4"},"hgnc":{"alias_symbol":["MCSPG","MEL-CSPG","MSK16","NG2","MCSP","HMW-MAA","CSPG4A"],"prev_symbol":[]},"alphafold":{"accession":"Q6UVK1","domains":[{"cath_id":"2.60.120.200","chopping":"27-193","consensus_level":"medium","plddt":82.9701,"start":27,"end":193},{"cath_id":"2.60.120.200","chopping":"202-381","consensus_level":"medium","plddt":77.2048,"start":202,"end":381},{"cath_id":"2.60.40.10","chopping":"431-548","consensus_level":"high","plddt":79.6853,"start":431,"end":548},{"cath_id":"2.60.40,2.60.40","chopping":"551-659","consensus_level":"medium","plddt":76.8087,"start":551,"end":659},{"cath_id":"2.60.40,2.60.40","chopping":"661-781","consensus_level":"medium","plddt":79.6473,"start":661,"end":781},{"cath_id":"2.60.40,2.60.40","chopping":"785-894","consensus_level":"medium","plddt":79.8757,"start":785,"end":894},{"cath_id":"2.60.40,2.60.40","chopping":"901-1013","consensus_level":"high","plddt":77.5647,"start":901,"end":1013},{"cath_id":"-","chopping":"1035-1096","consensus_level":"medium","plddt":83.5266,"start":1035,"end":1096},{"cath_id":"2.60.40","chopping":"1135-1229","consensus_level":"medium","plddt":80.8824,"start":1135,"end":1229},{"cath_id":"2.60.40.10","chopping":"1361-1468","consensus_level":"medium","plddt":81.7978,"start":1361,"end":1468},{"cath_id":"2.60.40.10","chopping":"1476-1578","consensus_level":"medium","plddt":84.7998,"start":1476,"end":1578},{"cath_id":"2.60.40,2.60.40","chopping":"1582-1704","consensus_level":"medium","plddt":79.5336,"start":1582,"end":1704},{"cath_id":"2.60.40","chopping":"1710-1827","consensus_level":"high","plddt":81.9561,"start":1710,"end":1827},{"cath_id":"2.60.40.10","chopping":"1835-1939","consensus_level":"medium","plddt":75.5768,"start":1835,"end":1939},{"cath_id":"2.60.40.10","chopping":"1943-2045","consensus_level":"medium","plddt":80.3264,"start":1943,"end":2045},{"cath_id":"2.60.40,2.60.40","chopping":"2049-2100_2107-2178","consensus_level":"high","plddt":79.4552,"start":2049,"end":2178}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6UVK1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q6UVK1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q6UVK1-F1-predicted_aligned_error_v6.png","plddt_mean":74.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CSPG4","jax_strain_url":"https://www.jax.org/strain/search?query=CSPG4"},"sequence":{"accession":"Q6UVK1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q6UVK1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q6UVK1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6UVK1"}},"corpus_meta":[{"pmid":"22004131","id":"PMC_22004131","title":"CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.","date":"2011","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/22004131","citation_count":163,"is_preprint":false},{"pmid":"20852124","id":"PMC_20852124","title":"CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.","date":"2010","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/20852124","citation_count":157,"is_preprint":false},{"pmid":"15588226","id":"PMC_15588226","title":"Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance.","date":"2004","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15588226","citation_count":152,"is_preprint":false},{"pmid":"20455858","id":"PMC_20455858","title":"CSPG4 in cancer: multiple roles.","date":"2010","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20455858","citation_count":102,"is_preprint":false},{"pmid":"24127551","id":"PMC_24127551","title":"Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.","date":"2013","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24127551","citation_count":95,"is_preprint":false},{"pmid":"21829586","id":"PMC_21829586","title":"Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21829586","citation_count":94,"is_preprint":false},{"pmid":"22893632","id":"PMC_22893632","title":"CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma.","date":"2012","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/22893632","citation_count":78,"is_preprint":false},{"pmid":"28536635","id":"PMC_28536635","title":"The regulatory mechanisms of NG2/CSPG4 expression.","date":"2017","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28536635","citation_count":70,"is_preprint":false},{"pmid":"25767619","id":"PMC_25767619","title":"Theranostic impact of NG2/CSPG4 proteoglycan in cancer.","date":"2015","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/25767619","citation_count":70,"is_preprint":false},{"pmid":"28668095","id":"PMC_28668095","title":"CSPG4: a prototype oncoantigen for translational immunotherapy studies.","date":"2017","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28668095","citation_count":64,"is_preprint":false},{"pmid":"34145250","id":"PMC_34145250","title":"Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34145250","citation_count":62,"is_preprint":false},{"pmid":"29302076","id":"PMC_29302076","title":"Candidate CSPG4 mutations and induced pluripotent stem cell modeling implicate oligodendrocyte progenitor cell dysfunction in familial schizophrenia.","date":"2018","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/29302076","citation_count":59,"is_preprint":false},{"pmid":"24874834","id":"PMC_24874834","title":"CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/24874834","citation_count":59,"is_preprint":false},{"pmid":"31426437","id":"PMC_31426437","title":"Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31426437","citation_count":58,"is_preprint":false},{"pmid":"29054751","id":"PMC_29054751","title":"NG2/CSPG4 and progranulin in the posttraumatic glial scar.","date":"2017","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29054751","citation_count":57,"is_preprint":false},{"pmid":"23559515","id":"PMC_23559515","title":"NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion.","date":"2013","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23559515","citation_count":57,"is_preprint":false},{"pmid":"22021902","id":"PMC_22021902","title":"Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22021902","citation_count":55,"is_preprint":false},{"pmid":"28842504","id":"PMC_28842504","title":"Functional defects in Clostridium difficile TcdB toxin uptake identify CSPG4 receptor-binding determinants.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28842504","citation_count":52,"is_preprint":false},{"pmid":"31779130","id":"PMC_31779130","title":"CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31779130","citation_count":50,"is_preprint":false},{"pmid":"30213051","id":"PMC_30213051","title":"The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30213051","citation_count":45,"is_preprint":false},{"pmid":"30550356","id":"PMC_30550356","title":"Structural deciphering of the NG2/CSPG4 proteoglycan multifunctionality.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30550356","citation_count":44,"is_preprint":false},{"pmid":"29924942","id":"PMC_29924942","title":"Deficient neurotrophic factors of CSPG4-type neural cell exosomes in Alzheimer disease.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29924942","citation_count":44,"is_preprint":false},{"pmid":"24740185","id":"PMC_24740185","title":"Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients.","date":"2014","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24740185","citation_count":42,"is_preprint":false},{"pmid":"27146852","id":"PMC_27146852","title":"Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination.","date":"2016","source":"Veterinary and comparative oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27146852","citation_count":42,"is_preprint":false},{"pmid":"15252841","id":"PMC_15252841","title":"Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients.","date":"2004","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15252841","citation_count":41,"is_preprint":false},{"pmid":"32900797","id":"PMC_32900797","title":"CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/32900797","citation_count":37,"is_preprint":false},{"pmid":"27425618","id":"PMC_27425618","title":"Mesenchymal Tumors Can Derive from Ng2/Cspg4-Expressing Pericytes with β-Catenin Modulating the Neoplastic Phenotype.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27425618","citation_count":37,"is_preprint":false},{"pmid":"21717063","id":"PMC_21717063","title":"The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.","date":"2011","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/21717063","citation_count":34,"is_preprint":false},{"pmid":"27037627","id":"PMC_27037627","title":"A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.","date":"2016","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27037627","citation_count":32,"is_preprint":false},{"pmid":"2916650","id":"PMC_2916650","title":"Cell surface molecules of human melanoma. Immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigenic systems.","date":"1989","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/2916650","citation_count":30,"is_preprint":false},{"pmid":"31137488","id":"PMC_31137488","title":"Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31137488","citation_count":30,"is_preprint":false},{"pmid":"15578703","id":"PMC_15578703","title":"Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15578703","citation_count":29,"is_preprint":false},{"pmid":"29462330","id":"PMC_29462330","title":"Cell surface chondroitin sulphate proteoglycan 4 (CSPG4) binds to the basement membrane heparan sulphate proteoglycan, perlecan, and is involved in cell adhesion.","date":"2018","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29462330","citation_count":28,"is_preprint":false},{"pmid":"24386429","id":"PMC_24386429","title":"Diversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsets.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24386429","citation_count":27,"is_preprint":false},{"pmid":"32331483","id":"PMC_32331483","title":"A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32331483","citation_count":27,"is_preprint":false},{"pmid":"29565434","id":"PMC_29565434","title":"Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.","date":"2018","source":"Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29565434","citation_count":25,"is_preprint":false},{"pmid":"31217827","id":"PMC_31217827","title":"Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma.","date":"2019","source":"Therapeutic advances in medical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31217827","citation_count":24,"is_preprint":false},{"pmid":"24932730","id":"PMC_24932730","title":"Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24932730","citation_count":24,"is_preprint":false},{"pmid":"33751759","id":"PMC_33751759","title":"Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4-DNA electrovaccination: A retrospective study on 155 cases.","date":"2021","source":"Veterinary and comparative oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33751759","citation_count":24,"is_preprint":false},{"pmid":"31006910","id":"PMC_31006910","title":"Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4-Akt-ERK signalling by inhibiting EGR1-dependent transcription.","date":"2019","source":"Phytotherapy research : PTR","url":"https://pubmed.ncbi.nlm.nih.gov/31006910","citation_count":23,"is_preprint":false},{"pmid":"23953863","id":"PMC_23953863","title":"The chrondroitin sulfate proteoglycan (CSPG4) regulates human trophoblast function.","date":"2013","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/23953863","citation_count":22,"is_preprint":false},{"pmid":"33815067","id":"PMC_33815067","title":"Myelin Debris Stimulates NG2/CSPG4 Expression in Bone Marrow-Derived Macrophages in the Injured Spinal Cord.","date":"2021","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33815067","citation_count":22,"is_preprint":false},{"pmid":"29196603","id":"PMC_29196603","title":"Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29196603","citation_count":21,"is_preprint":false},{"pmid":"25016058","id":"PMC_25016058","title":"A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissues.","date":"2014","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/25016058","citation_count":21,"is_preprint":false},{"pmid":"28657611","id":"PMC_28657611","title":"CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL.","date":"2017","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/28657611","citation_count":20,"is_preprint":false},{"pmid":"12710131","id":"PMC_12710131","title":"Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi.","date":"2003","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12710131","citation_count":20,"is_preprint":false},{"pmid":"29812912","id":"PMC_29812912","title":"Proximity Labeling by a Recombinant APEX2-FGF1 Fusion Protein Reveals Interaction of FGF1 with the Proteoglycans CD44 and CSPG4.","date":"2018","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29812912","citation_count":20,"is_preprint":false},{"pmid":"40082557","id":"PMC_40082557","title":"Human CSPG4-targeting CAR-macrophages inhibit melanoma growth.","date":"2025","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/40082557","citation_count":19,"is_preprint":false},{"pmid":"31195686","id":"PMC_31195686","title":"CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31195686","citation_count":19,"is_preprint":false},{"pmid":"31769737","id":"PMC_31769737","title":"In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model.","date":"2020","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/31769737","citation_count":19,"is_preprint":false},{"pmid":"30306660","id":"PMC_30306660","title":"NG2 expression in NG2 glia is regulated by binding of SoxE and bHLH transcription factors to a Cspg4 intronic enhancer.","date":"2018","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/30306660","citation_count":19,"is_preprint":false},{"pmid":"36291817","id":"PMC_36291817","title":"Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36291817","citation_count":18,"is_preprint":false},{"pmid":"32006045","id":"PMC_32006045","title":"Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids.","date":"2020","source":"HNO","url":"https://pubmed.ncbi.nlm.nih.gov/32006045","citation_count":17,"is_preprint":false},{"pmid":"34078123","id":"PMC_34078123","title":"CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.","date":"2021","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/34078123","citation_count":16,"is_preprint":false},{"pmid":"37312451","id":"PMC_37312451","title":"A chimeric human/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma.","date":"2023","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37312451","citation_count":16,"is_preprint":false},{"pmid":"33649790","id":"PMC_33649790","title":"Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF.","date":"2021","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33649790","citation_count":15,"is_preprint":false},{"pmid":"35580930","id":"PMC_35580930","title":"Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35580930","citation_count":15,"is_preprint":false},{"pmid":"34638301","id":"PMC_34638301","title":"Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34638301","citation_count":14,"is_preprint":false},{"pmid":"36795751","id":"PMC_36795751","title":"Cspg4 microglia contribute to microgliosis during neurodegeneration.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36795751","citation_count":14,"is_preprint":false},{"pmid":"27292772","id":"PMC_27292772","title":"Functional roles of CSPG4/NG2 in chondrosarcoma.","date":"2016","source":"International journal of experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27292772","citation_count":13,"is_preprint":false},{"pmid":"24258997","id":"PMC_24258997","title":"Detection of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma.","date":"2014","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/24258997","citation_count":13,"is_preprint":false},{"pmid":"36685663","id":"PMC_36685663","title":"NG2/CSPG4 regulates cartilage degeneration during TMJ osteoarthritis.","date":"2022","source":"Frontiers in dental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36685663","citation_count":12,"is_preprint":false},{"pmid":"33727640","id":"PMC_33727640","title":"NG2/CSPG4, CD146/MCAM and VAP1/AOC3 are regulated by myocardin-related transcription factors in smooth muscle cells.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33727640","citation_count":12,"is_preprint":false},{"pmid":"34952462","id":"PMC_34952462","title":"Glutaredoxin 2 promotes SP-1-dependent CSPG4 transcription and migration of wound healing NG2 glia and glioma cells: Enzymatic Taoism.","date":"2021","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/34952462","citation_count":12,"is_preprint":false},{"pmid":"37432459","id":"PMC_37432459","title":"CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate.","date":"2023","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37432459","citation_count":11,"is_preprint":false},{"pmid":"35927993","id":"PMC_35927993","title":"A Linarin Derivative Protects against Ischemia-Induced Neuronal Injury in Mice by Promoting Cerebral Blood Flow Recovery via KDELR-Dependent CSPG4 Activation.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/35927993","citation_count":11,"is_preprint":false},{"pmid":"40425233","id":"PMC_40425233","title":"B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer.","date":"2025","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40425233","citation_count":9,"is_preprint":false},{"pmid":"39409881","id":"PMC_39409881","title":"Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma.","date":"2024","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/39409881","citation_count":9,"is_preprint":false},{"pmid":"37901209","id":"PMC_37901209","title":"Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37901209","citation_count":9,"is_preprint":false},{"pmid":"37747247","id":"PMC_37747247","title":"Nectin-3 and shed forms of CSPG4 can serve as epithelial cell receptors for Clostridioides difficile TcdB.","date":"2023","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/37747247","citation_count":9,"is_preprint":false},{"pmid":"38309500","id":"PMC_38309500","title":"Chondroitin sulfate modification of CSPG4 regulates the maintenance and differentiation of glioma-initiating cells via integrin-associated signaling.","date":"2024","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38309500","citation_count":9,"is_preprint":false},{"pmid":"37993874","id":"PMC_37993874","title":"CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.","date":"2023","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/37993874","citation_count":8,"is_preprint":false},{"pmid":"25706398","id":"PMC_25706398","title":"Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts.","date":"2015","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/25706398","citation_count":8,"is_preprint":false},{"pmid":"21573118","id":"PMC_21573118","title":"Specificity of mimotope-induced anti-high molecular weight-melanoma associated antigen (HMW-MAA) antibodies does not ensure biological activity.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21573118","citation_count":8,"is_preprint":false},{"pmid":"32599896","id":"PMC_32599896","title":"Chondroitin Sulphate Proteoglycan 4 (NG2/CSPG4) Localization in Low- and High-Grade Gliomas.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32599896","citation_count":7,"is_preprint":false},{"pmid":"15846144","id":"PMC_15846144","title":"Cross-reactivity of mimotopes with a monoclonal antibody against the high molecular weight melanoma-associated antigen (HMW-MAA) does not predict cross-reactive immunogenicity.","date":"2005","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/15846144","citation_count":7,"is_preprint":false},{"pmid":"35891187","id":"PMC_35891187","title":"Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers.","date":"2022","source":"Vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/35891187","citation_count":6,"is_preprint":false},{"pmid":"36634519","id":"PMC_36634519","title":"Trophoblast-specific knockdown of CSPG4 expression causes pregnancy complications with poor placentation in mice.","date":"2023","source":"Reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/36634519","citation_count":6,"is_preprint":false},{"pmid":"34102261","id":"PMC_34102261","title":"The Function of NG2/CSPG4-expressing Cells in the Rat Spinal Cord Injury: An Immunoelectron Microscopy Study.","date":"2021","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34102261","citation_count":6,"is_preprint":false},{"pmid":"40720084","id":"PMC_40720084","title":"Targeting CSPG4 enhances the anti-tumor activity of CAR-NK cells for glioblastoma.","date":"2025","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/40720084","citation_count":5,"is_preprint":false},{"pmid":"36972308","id":"PMC_36972308","title":"Discovery of Hippo signaling as a regulator of CSPG4 expression and as a therapeutic target for Clostridioides difficile disease.","date":"2023","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/36972308","citation_count":5,"is_preprint":false},{"pmid":"30501829","id":"PMC_30501829","title":"Effect of TGFβ1 and nAG on Astrocyte Cultures: A Study of Astrocyte Proliferation and the Expression of GFAP, CSPG4, S100B and IL-6.","date":"2018","source":"Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","url":"https://pubmed.ncbi.nlm.nih.gov/30501829","citation_count":5,"is_preprint":false},{"pmid":"39686677","id":"PMC_39686677","title":"Identification of CSPG4 as a Biomarker and Therapeutic Target for Infantile Post-Hemorrhagic Hydrocephalus via Multi-Omics Analysis.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39686677","citation_count":4,"is_preprint":false},{"pmid":"38895447","id":"PMC_38895447","title":"CSPG4-targeting CAR-macrophages inhibit melanoma growth.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38895447","citation_count":3,"is_preprint":false},{"pmid":"40847369","id":"PMC_40847369","title":"B7-H3 and CSPG4-targeted CAR T cells as potent effectors in anaplastic thyroid cancer.","date":"2025","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/40847369","citation_count":3,"is_preprint":false},{"pmid":"37849763","id":"PMC_37849763","title":"Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37849763","citation_count":3,"is_preprint":false},{"pmid":"36768830","id":"PMC_36768830","title":"VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36768830","citation_count":3,"is_preprint":false},{"pmid":"29540359","id":"PMC_29540359","title":"CSPG4 Shows Promise for Glioblastoma CAR T Therapy.","date":"2018","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29540359","citation_count":3,"is_preprint":false},{"pmid":"39566199","id":"PMC_39566199","title":"Cspg4 sculpts oligodendrocyte precursor cell morphology.","date":"2024","source":"Differentiation; research in biological diversity","url":"https://pubmed.ncbi.nlm.nih.gov/39566199","citation_count":2,"is_preprint":false},{"pmid":"40791371","id":"PMC_40791371","title":"Neuroligin-3 interaction with CSPG4 regulates normal and malignant glial precursors through PIEZO1.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/40791371","citation_count":2,"is_preprint":false},{"pmid":"40059815","id":"PMC_40059815","title":"Clinical evaluation of HuDo-CSPG4 DNA electroporation as adjuvant treatment for canine oral malignant melanoma: comparison of two vaccination protocols.","date":"2025","source":"The veterinary quarterly","url":"https://pubmed.ncbi.nlm.nih.gov/40059815","citation_count":2,"is_preprint":false},{"pmid":"39863819","id":"PMC_39863819","title":"CSPG4 overexpression implicates higher risks of recurrence and tumorigenesis after surgical intervention of vocal fold Leukoplakia.","date":"2025","source":"European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/39863819","citation_count":2,"is_preprint":false},{"pmid":"34344877","id":"PMC_34344877","title":"Identification of a germline CSPG4 variation in a family with neurofibromatosis type 1-like phenotype.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34344877","citation_count":2,"is_preprint":false},{"pmid":"28011196","id":"PMC_28011196","title":"Isolating subpopulations of human epidermal basal cells based on polyclonal serum against trypsin-resistant CSPG4 epitopes.","date":"2016","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/28011196","citation_count":2,"is_preprint":false},{"pmid":"39149260","id":"PMC_39149260","title":"Cspg4 sculpts oligodendrocyte precursor cell morphology.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39149260","citation_count":1,"is_preprint":false},{"pmid":"40700516","id":"PMC_40700516","title":"Enhanced diagnostic potential of CSPG4 in melanoma and nevi: a comparative study with PRAME, CDC7 and Ki67.","date":"2025","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/40700516","citation_count":1,"is_preprint":false},{"pmid":"38470254","id":"PMC_38470254","title":"CSPG4-dependent cytotoxicity for C. difficile TcdB is influenced by extracellular calcium and chondroitin sulfate.","date":"2024","source":"mSphere","url":"https://pubmed.ncbi.nlm.nih.gov/38470254","citation_count":1,"is_preprint":false},{"pmid":"39563514","id":"PMC_39563514","title":"CSPG4 involvement in endometrial decidualization contributes to the pathogenesis of preeclampsia†.","date":"2025","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/39563514","citation_count":1,"is_preprint":false},{"pmid":"40769519","id":"PMC_40769519","title":"Possible Involvement of CSPG4 in Promoting Endothelial Cell Migration and Contributing to Angiogenesis during Skeletal Muscle Regeneration and Development in the Rat.","date":"2025","source":"Animal science journal = Nihon chikusan Gakkaiho","url":"https://pubmed.ncbi.nlm.nih.gov/40769519","citation_count":1,"is_preprint":false},{"pmid":"40724839","id":"PMC_40724839","title":"CSPG4.CAR-T Cells Modulate Extracellular Matrix Remodeling in DMD Cardiomyopathy.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40724839","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53436,"output_tokens":8902,"usd":0.146919,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18828,"output_tokens":3945,"usd":0.096382,"stage2_stop_reason":"end_turn"},"total_usd":0.243301,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2021,\n      \"finding\": \"Cryo-EM structure of TcdB-CSPG4 complex revealed that CSPG4 is a receptor for C. difficile toxin TcdB, with a unique binding site composed of multiple discontinuous regions across TcdB. CSPG4-knockout mice showed reduced colonic tissue damage during C. difficile infections, and mutations selectively disrupting CSPG4 binding reduced TcdB toxicity in mice. Bezlotoxumab blocks CSPG4 binding to TcdB via an allosteric mechanism.\",\n      \"method\": \"Cryo-EM structure determination, site-directed mutagenesis, CSPG4-knockout mouse model, in vivo toxicity assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure with functional mutagenesis validation and in vivo KO model, multiple orthogonal methods in single study\",\n      \"pmids\": [\"34145250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The CSPG4-binding site on TcdB maps to a region at the junction of the translocation and CROP domains, requiring at least three CROP short repeats for binding and full toxicity on CSPG4-expressing cells. The anti-TcdB antibody bezlotoxumab prevents CSPG4 binding by overlapping with the CSPG4-binding site in the first three short repeats.\",\n      \"method\": \"C-terminal truncation series, receptor-binding mutant screen, cell intoxication assays, competitive binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic mutagenesis with multiple truncation constructs and functional validation, single lab but orthogonal methods\",\n      \"pmids\": [\"28842504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Extracellular Ca2+ promotes preferential TcdB binding to CSPG4 (protein core), while the chondroitin sulfate (CS) moiety of CSPG4 does not enhance Ca2+-mediated binding but instead influences the rate of TcdB cell entry after surface binding.\",\n      \"method\": \"TcdB receptor-binding mutants, cell lines with varied receptor profiles, Ca2+ manipulation assays, binding and cytotoxicity assays\",\n      \"journal\": \"mSphere\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-binding mutants and cell-line panel with two orthogonal endpoints (binding vs. entry), single lab\",\n      \"pmids\": [\"38470254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Nectin-3 and shed forms of CSPG4 (shed by fibroblasts along the crypt-surface axis) serve as epithelial cell receptors for C. difficile TcdB on colonic epithelial cells, with CSPG4 localized at epithelial cell junctions as visualized by immunofluorescence microscopy on colonic tissue.\",\n      \"method\": \"Immunofluorescence microscopy on colonic tissue sections\",\n      \"journal\": \"mBio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct tissue localization experiment revealing receptor access mechanism, single lab, single primary method\",\n      \"pmids\": [\"37747247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CSPG4 binds to the basement membrane proteoglycan perlecan via hydrophobic protein-protein interactions involving multiple sites on perlecan including the C-terminal region. This CSPG4-perlecan interaction supports cell adhesion and actin polymerization.\",\n      \"method\": \"Immunopurification of CSPG4 from melanoma cell lines, co-complex formation assay, mechanistic domain-mapping with purified perlecan fragments, actin polymerization assay\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical pulldown with domain-mapping and functional cell adhesion/actin readout, single lab\",\n      \"pmids\": [\"29462330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NG2/CSPG4 interacts with collagen type VI (Col VI) through reciprocal binding sites identified using dominant-negative NG2 mutants and purified Col VI domain fragments. NG2-Col VI binding triggers activation of PI-3K-dependent cell survival and cell adhesion/migration signaling pathways, controlling sarcoma cell adhesion and motility.\",\n      \"method\": \"Dominant-negative NG2 mutant cells, purified Col VI domain fragments, RNAi knockdown, ectopic transduction of full-length/deletion NG2 constructs, in vitro adhesion/motility assays, xenograft models\",\n      \"journal\": \"Journal of molecular cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal approaches (domain-deletion mutants, RNAi, ectopic expression, domain-fragment competition) converging on binding sites and PI-3K pathway activation\",\n      \"pmids\": [\"23559515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CSPG4-specific antibody (scFv-FcC21) inhibits tumor cell growth and migration by blocking activation of ERK (required for growth) and focal adhesion kinase (FAK) signaling (required for migration) in CSPG4-positive tumor cells.\",\n      \"method\": \"Phage display antibody generation, in vitro growth and migration assays, signaling pathway analysis (ERK and FAK phosphorylation), in vivo xenograft tumor growth assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function via antibody blockade with defined signaling readouts and in vivo confirmation, single lab\",\n      \"pmids\": [\"22021902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CSPG4-specific mAb 225.28 inhibits TNBC cell growth, adhesion, and migration in vitro, with antitumor mechanisms including increased apoptosis, reduced mitotic activity, decreased tumor vascularity, and reduced activation of survival/proliferation/metastasis signaling pathways.\",\n      \"method\": \"In vitro growth, adhesion, and migration assays; apoptosis assays; in vivo metastasis and orthotopic xenograft models; signaling pathway analysis\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vitro and in vivo endpoints with mechanistic pathway readouts, single lab\",\n      \"pmids\": [\"20852124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CSPG4 mediates mesothelioma cell adhesion via engagement of extracellular matrix (ECM); mAb TP41.2 blockade of CSPG4 decreases phosphorylation of FAK and AKT, reduces cyclin D1 expression, and induces apoptosis, establishing CSPG4 as a key upstream regulator of FAK/AKT/cyclin D1 signaling in mesothelioma.\",\n      \"method\": \"CSPG4 antibody blockade, adhesion assays, immunoblotting for FAK and AKT phosphorylation, cyclin D1 expression, apoptosis assays, in vivo SCID mouse xenograft\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody-mediated loss-of-function with mechanistic signaling readouts, in vitro and in vivo confirmation, single lab\",\n      \"pmids\": [\"22893632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NG2/CSPG4 overexpression in GBM cells increases tumor growth rate, angiogenesis, and vascular permeability in vivo. NG2 knockdown (via lentiviral shRNA) in patient-derived GBM xenografts and melanoma tumors reduced tumor growth, oedema, and angiogenesis, and normalized vascular function while increasing invasion.\",\n      \"method\": \"NG2-overexpressing GBM xenografts, lentiviral shRNA knockdown in intracranial patient GBM xenografts and subcutaneous melanoma tumors, tumor growth measurements, vascular permeability and angiogenesis assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function in vivo models with multiple orthogonal phenotypic readouts, single lab\",\n      \"pmids\": [\"21829586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NG2/CSPG4 knockdown in established soft-tissue sarcoma cells decreased tumor volume by ~two-thirds and cell proliferation by 50%; NG2/CSPG4 deletion at tumor initiation paradoxically produced larger tumors associated with downregulation of insulin-like growth factor binding protein (Igfbp) genes, indicating stage-dependent and divergent roles for NG2/CSPG4 in sarcoma.\",\n      \"method\": \"shRNA knockdown in human sarcoma xenografts, autochthonous mouse sarcoma model with conditional Ng2/Cspg4 deletion, NG2 antibody immunotherapy, gene expression profiling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple complementary models (KD, KO, antibody) with mechanistic gene expression data, single lab\",\n      \"pmids\": [\"29196603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Furanodienone (FUR) suppresses CSPG4 expression in temozolomide-resistant GBM cells by inhibiting EGR1-dependent transcription of CSPG4, thereby downregulating CSPG4-Akt-ERK signaling, suppressing inflammatory responses, and activating caspase-dependent apoptosis.\",\n      \"method\": \"In vitro cytotoxicity assays, immunofluorescence, dual-luciferase reporter assay for EGR1-mediated CSPG4 transcription, western blotting for pathway components\",\n      \"journal\": \"Phytotherapy research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — luciferase reporter and pathway analysis establish EGR1-CSPG4 transcriptional link with functional downstream signaling, single lab\",\n      \"pmids\": [\"31006910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Hippo signaling pathway regulates CSPG4 expression: TcdB-resistant HeLa cells that lost CSPG4 mRNA showed correlated changes in Hippo and estrogen signaling pathways. CRISPR-mediated deletion of key Hippo transcriptional regulators and chemical modulation altered CSPG4 expression. Pharmacological inactivation of Hippo (XMU-MP-1) protected mice from C. difficile disease.\",\n      \"method\": \"TcdB-resistance selection, mRNA expression profiling, integrated pathway analysis, CRISPR deletion of Hippo pathway regulators, chemical modulation, mouse C. difficile disease model\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR, chemical modulation, and in vivo validation provide multiple orthogonal lines of evidence for Hippo regulation of CSPG4, single lab\",\n      \"pmids\": [\"36972308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NG2/CSPG4 expression in smooth muscle cells is regulated by myocardin-related transcription factors (MRTFs: MYOCD, MRTF-A/MKL1, MRTF-B/MKL2) acting through serum response factor (SRF). MRTF overexpression increased CSPG4 mRNA and protein; SRF silencing reduced CSPG4 transcript levels; CSPG4 responded to MRTF-SRF inhibitor CCG-1423 and to actin dynamics.\",\n      \"method\": \"Bioinformatics correlation, MRTF overexpression in human smooth muscle cells, SRF silencing, promoter reporter assays, pharmacological inhibition with CCG-1423\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with transcriptional reporter assays and pharmacological validation, single lab\",\n      \"pmids\": [\"33727640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The cytosolic isoform of Glutaredoxin 2 (Grx2c) regulates the redox state of transcription factor SP-1, modulating its binding affinity to both the promoter and an enhancer region of the CSPG4 gene, thereby increasing NG2 expression and promoting migration of NG2 glia and invasion of glioma cells.\",\n      \"method\": \"In vitro human cell lines, ex vivo mouse primary cells, in vivo zebrafish models, glioblastoma patient tissue samples, SP-1 redox state and DNA-binding analysis\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple model systems (in vitro, ex vivo, in vivo) and mechanistic link from Grx2c redox to SP-1 binding to CSPG4 transcription, single lab\",\n      \"pmids\": [\"34952462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A 1.45 kb intronic enhancer of the mouse Cspg4 gene directs transcription to NG2 glia but not pericytes in vitro and in transgenic mice. This enhancer contains binding sites for SoxE and basic helix-loop-helix (bHLH) transcription factors, whose cooperative binding augments enhancer activity; mutations in these binding elements abolished enhancer activity.\",\n      \"method\": \"In vitro enhancer assays, EGFP reporter transgenic mice, site-directed mutagenesis of transcription factor binding elements\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reporter + transgenic in vivo validation + mutagenesis of binding elements, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"30306660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"APEX2-FGF1 proximity labeling identified CSPG4 (NG2) and CD44 as novel FGF1 binding partners at the cell surface. CSPG4 and FGF1 colocalize at the cell surface, suggesting CSPG4 acts as a storage molecule creating a reservoir of FGF1 at the cell surface.\",\n      \"method\": \"APEX2-FGF1 fusion protein proximity biotin labeling, mass spectrometry identification, co-localization imaging, signaling assay for functional validation\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proximity labeling with MS identification and colocalization confirmation, single lab, novel interaction\",\n      \"pmids\": [\"29812912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CSPG4 siRNA knockdown in human extravillous trophoblast (EVT) cells stimulated proliferation and decreased migration/invasion, demonstrating that CSPG4 promotes trophoblast migration and invasion. IL11 and LIF cytokines stimulated CSPG4 mRNA and protein expression in first-trimester placental villous explants.\",\n      \"method\": \"siRNA knockdown in HTR8/SVneo cells, proliferation and migration/invasion assays, cytokine stimulation of placental villous explants\",\n      \"journal\": \"Placenta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA loss-of-function with defined cellular phenotype readouts and cytokine regulation, single lab\",\n      \"pmids\": [\"23953863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Trophoblast-specific CSPG4 knockdown in mice caused frequent fetal loss and poor placentation, with reduced placental weight. CSPG4-knockout trophoblast cells showed inhibited proliferation and invasion, with reduced AKT and ERK phosphorylation and decreased MMP2 and MMP9 expression.\",\n      \"method\": \"Trophoblast-specific lentiviral CSPG4 knockdown mouse model, CSPG4-knockout trophoblast cell line, proliferation and invasion assays, western blotting for AKT/ERK phosphorylation and MMP expression\",\n      \"journal\": \"Reproductive biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KD mouse model with cellular mechanistic validation (KO cell line + signaling), single lab\",\n      \"pmids\": [\"36634519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Chondroitin sulfate (CS) modification on CSPG4 is required for glioma-initiating cell (GIC) maintenance. CS degradation on CSPG4 by ChondroitinaseABC induced GIC differentiation (inhibited by exogenous CS addition). During GIC differentiation, de-CS-modified CSPG4 (lacking CS chains) interacts with integrin αV, activating integrin-ERK signaling that promotes differentiation; CS-modified CSPG4 does not interact with integrin αV.\",\n      \"method\": \"ChondroitinaseABC treatment, XYLT1 knockdown, CSPG4 knockdown, co-immunoprecipitation of CSPG4 with integrin αV, cyclic-RGD inhibitor assays, proteo-genomics of patient-derived GIC clones\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — enzymatic modification, genetic knockdown, co-IP, and pharmacological inhibition all converging on CS-CSPG4–integrin αV axis, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"38309500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NG2/CSPG4 is required for mechanical activation of ERK 1/2 in TMJ cartilage cells; NG2/CSPG4 knockout mice have more severe cartilage degeneration during TMJ osteoarthritis, elevated OA proteases, and suppressed OA matrix synthesis genes. In vitro, NG2/CSPG4 KO cells fail to mechanically activate ERK 1/2 under compression loading.\",\n      \"method\": \"Surgical destabilization-induced TMJ OA in NG2/CSPG4 KO mice, transcriptome and protein analysis, compression bioreactor on cell-agarose-collagen scaffolds, ERK 1/2 phosphorylation assays\",\n      \"journal\": \"Frontiers in dental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO model combined with in vitro mechanobiological assay, multiple readouts, single lab\",\n      \"pmids\": [\"36685663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Myelin debris from damaged myelin sheaths increases NG2/CSPG4 expression in bone marrow-derived macrophages (BMDMΦ) after spinal cord injury, and these NG2/CSPG4-expressing macrophages exhibit enhanced proliferation and decreased phagocytic capacity.\",\n      \"method\": \"Spinal cord injury mouse model, identification of BMDMΦ as NG2/CSPG4 source, myelin debris stimulation in vitro with functional assays (proliferation, phagocytosis)\",\n      \"journal\": \"Frontiers in cellular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo SCI model combined with in vitro mechanistic stimulation and functional readouts, single lab\",\n      \"pmids\": [\"33815067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"shRNA knockdown of CSPG4/NG2 in the JJ012 chondrosarcoma cell line reduced cell proliferation and migration, decreased gene expression of MMP3 and ADAMTS4 proteases, and increased sensitivity to doxorubicin.\",\n      \"method\": \"Stable shRNA knockdown, cell proliferation and migration assays, gene expression analysis of MMP3 and ADAMTS4, doxorubicin sensitivity assay\",\n      \"journal\": \"International journal of experimental pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — stable KD with multiple functional readouts, single lab, single cell line\",\n      \"pmids\": [\"27292772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Using lineage tracing in mice, bone and soft-tissue sarcomas (driven by Trp53 deletion) and desmoid tumors (driven by Apc mutation) can originate from Ng2/Cspg4-expressing pericytes. β-catenin stabilization in Ng2/Cspg4+ cells caused desmoid tumors, while Trp53 deletion caused sarcomas. β-catenin signaling was inhibited in sarcomas versus precursor pericytes, and β-catenin activation inhibited sarcoma formation and growth.\",\n      \"method\": \"Cre-based lineage tracing from Ng2/Cspg4-expressing cells, conditional Trp53 deletion and Apc mutation mouse models, gene expression profiling, β-catenin activation experiments\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic lineage tracing with conditional oncogene models and mechanistic β-catenin pathway validation, multiple orthogonal approaches, single lab\",\n      \"pmids\": [\"27425618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRAF and MEK inhibitor treatment of BRAF-mutant melanoma cells results in markedly reduced CSPG4 protein and mRNA levels (not via increased shedding). Patient-derived matched tumor samples following kinase inhibitor therapy showed decreased numbers of CSPG4-positive cells compared to pre-therapy samples.\",\n      \"method\": \"Flow cytometry, immunofluorescence, western blotting, qPCR, measurement of CSPG4 in culture supernatants, patient tumor sample IHC\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple protein and mRNA assays plus patient sample validation linking BRAF/MEK signaling to CSPG4 expression regulation, single lab\",\n      \"pmids\": [\"33649790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"iPSC-derived oligodendrocyte precursor cells (OPCs) from carriers of the CSPG4-A131T missense mutation exhibited abnormal post-translational processing and subcellular localization of mutant NG2/CSPG4, aberrant cellular morphology, reduced viability, and impaired myelination potential. Transfection of healthy OPCs with either CSPG4-A131T or CSPG4-V901G mutants confirmed pathogenic effects on cell survival.\",\n      \"method\": \"iPSC-derived OPCs from mutation carriers, protein processing/localization assays, morphology quantification, viability assays, myelination assay, transfection of healthy OPCs with mutant constructs, in vivo diffusion tensor imaging\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient-derived iPSC model with multiple cellular phenotype readouts and confirmation by transfection in healthy cells, single lab\",\n      \"pmids\": [\"29302076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"NLGN3 (neuroligin-3) shed by neurons interacts directly with CSPG4 on glioma cells and oligodendrocyte precursor cells (OPCs), facilitating CSPG4 shedding by ADAM10. This NLGN3-CSPG4 interaction and consequent shedding alter membrane tension, activating PIEZO1 mechanosensitive channels and causing membrane depolarization, maintaining OPCs in an undifferentiated state and promoting glioma proliferation.\",\n      \"method\": \"Biochemical interaction assays (NLGN3-CSPG4 binding), ADAM10 shedding assays, PIEZO1 channel activity measurements, membrane tension assays, glioma proliferation assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — preprint describing novel molecular pathway with biochemical interaction and functional validation but not yet peer reviewed, single lab\",\n      \"pmids\": [\"40791371\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cspg4-expressing microglia represent a specific proliferative subset during neurodegeneration. Their transcriptomic signature is enriched for cell cycle genes and depleted for neuroinflammation/phagocytosis genes. Pathological α-synuclein evokes proliferation of quiescent Cspg4 microglia. Cspg4 microglia grafts show higher survival than Cspg4-negative microglia upon transplantation into adult brain with depleted endogenous microglia.\",\n      \"method\": \"Transcriptomic profiling of Cspg4 microglia subsets, PD mouse models, pathological α-synuclein stimulation, microglia transplantation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptomics plus functional in vivo transplantation and α-synuclein stimulation experiments, single lab\",\n      \"pmids\": [\"36795751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Zebrafish lacking cspg4 function produce normal numbers of oligodendrocyte lineage cells that undergo proper differentiation and produce myelin sheaths of normal number and length, but OPC morphology is aberrant in mutant larvae, establishing that Cspg4 specifically regulates OPC morphogenesis but is not required for OLC differentiation or myelination.\",\n      \"method\": \"cspg4 loss-of-function zebrafish model, OPC morphology quantification, OLC differentiation assessment, myelin sheath number and length measurement\",\n      \"journal\": \"Differentiation; research in biological diversity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic KO in vivo with multiple orthogonal readouts distinguishing morphogenesis from differentiation/myelination, single lab\",\n      \"pmids\": [\"39566199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CSPG4 expressed on mesenchymal progenitor cells (MPCs) promotes vascular endothelial cell migration; CSPG4 KO in MPCs abrogated upregulation of endothelial migration. In CSPG4 KO rats, skeletal muscle development was perturbed with impaired angiogenesis, and muscle regeneration showed reduced CD31-positive cells at regenerating sites.\",\n      \"method\": \"CSPG4 KO rat model, muscle regeneration assay, co-culture of CSPG4-expressing vs KO MPCs with endothelial cells, endothelial cell migration assay, CD31 immunostaining\",\n      \"journal\": \"Animal science journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO rat model combined with in vitro co-culture mechanistic assay, multiple readouts, single lab\",\n      \"pmids\": [\"40769519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CSPG4 silencing in choroid plexus cells suppressed ferroptosis, cell adhesion function, and intracellular Ca2+ flow in a post-hemorrhagic hydrocephalus (PHH) model, suggesting CSPG4 participates in ferroptosis and Ca2+ signaling relevant to PHH pathophysiology.\",\n      \"method\": \"CSPG4 silencing in vitro cellular experiments, rat PHH models, ferroptosis assay, cell adhesion assay, intracellular Ca2+ flow measurement\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, KD with functional readouts but mechanistic pathway placement preliminary, choroid plexus context not well established for CSPG4\",\n      \"pmids\": [\"39686677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CSPG4 expression during decidualization is required for trophoblast invasion: CSPG4 knockdown in endometrial stromal cells inhibited decidualization and subsequently inhibited trophoblast invasion. CSPG4 expression increases during artificially induced decidualization in both human cells and mouse models.\",\n      \"method\": \"siRNA knockdown of CSPG4 in endometrial stromal cells, decidualization induction assay, trophoblast invasion assay, qPCR and western blotting in pseudopregnant and pregnant mouse endometria\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — siRNA KD with downstream trophoblast invasion assay and in vivo mouse validation, single lab\",\n      \"pmids\": [\"39563514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A germline V2097M variant in CSPG4 promoted cell proliferation by activating the MAPK/ERK signaling pathway via hindering ectodomain cleavage of CSPG4, as demonstrated by in vitro functional studies.\",\n      \"method\": \"Targeted sequencing, whole-exome sequencing, in vitro functional cell proliferation assays, MAPK/ERK signaling analysis, ectodomain cleavage assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single variant, in vitro with limited mechanistic detail in abstract about how cleavage hindering is established\",\n      \"pmids\": [\"34344877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BLR (linarin derivative) increased CSPG4 gene expression and enhanced CSPG4 membrane localization, with downstream signaling protein expression associated with KDEL receptor (KDELR) activation; activated KDELR further increased phosphorylation of MAPKs. CSPG4 upregulation correlated with increased cerebral blood flow and protection from ischemic brain injury.\",\n      \"method\": \"Mouse MCAO model, RNA sequencing, coimmunoprecipitation, western blotting, laser speckle contrast imaging\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — co-IP and gene expression data with in vivo model, but mechanistic link between KDELR-CSPG4 interaction and downstream MAPK is incompletely established from abstract alone, single lab\",\n      \"pmids\": [\"35927993\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CSPG4 (NG2/HMW-MAA) is a large transmembrane chondroitin sulfate proteoglycan that functions as a multi-functional cell surface scaffold: it acts as a primary receptor for C. difficile TcdB toxin (binding via the toxin's CROP domain in a Ca2+-dependent manner, with its CS chains facilitating cell entry); it engages extracellular matrix ligands including collagen type VI and perlecan to promote cell adhesion and motility via PI-3K and FAK signaling; it modulates growth factor receptor (RTK) and integrin signaling to sustain ERK1/2 and AKT activation supporting tumor cell proliferation, survival, and angiogenesis; its CS modification controls interactions with integrin αV to regulate glioma stem cell maintenance versus differentiation; it interacts with shed NLGN3 to activate ADAM10-mediated shedding and PIEZO1 mechanosensitive channel signaling in glial precursors; its transcription is regulated by SoxE/bHLH factors (via an intronic enhancer), MRTF-SRF, SP-1 (redox-regulated by Grx2c), EGR1, and the Hippo pathway; and loss-of-function studies establish roles in OPC morphogenesis, trophoblast invasion, angiogenesis during muscle regeneration, and cartilage mechanical homeostasis via ERK1/2.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CSPG4 (NG2/HMW-MAA) is a large transmembrane chondroitin sulfate proteoglycan that functions as a multifunctional cell-surface scaffold coupling extracellular matrix and growth-factor cues to intracellular survival, proliferation, and motility signaling [#5, #19]. It serves as a host receptor for Clostridioides difficile toxin TcdB: the binding interface maps to discontinuous regions spanning the junction of the toxin's translocation and CROP domains, requires at least three CROP short repeats, is potentiated by extracellular Ca2+ acting on the CSPG4 protein core, and is blocked by the therapeutic antibody bezlotoxumab; CSPG4-knockout mice are protected from colonic damage, and the chondroitin sulfate (CS) chains accelerate toxin cell entry after surface binding [#0, #1, #2]. In epithelial tissue, junctional and fibroblast-shed CSPG4 provides receptor access along the colonic crypt-surface axis [#3]. As an adhesion and signaling receptor, CSPG4 engages matrix ligands including collagen type VI and the basement-membrane proteoglycan perlecan to drive actin polymerization, adhesion, and motility through PI-3K and FAK signaling [#4, #5], and sustains FAK/AKT/ERK and cyclin D1 signaling that supports tumor cell proliferation, survival, migration, and angiogenesis across melanoma, mesothelioma, sarcoma, and glioma [#6, #8, #9]. Its CS modification acts as a molecular switch: CS-bearing CSPG4 maintains glioma-initiating cells, whereas CS removal permits CSPG4 binding to integrin \\u03b1V and activation of integrin-ERK signaling that promotes differentiation [#19]. CSPG4 abundance is set transcriptionally by SoxE/bHLH factors acting through an NG2-glia-specific intronic enhancer, by MRTF-SRF, by redox-regulated SP-1, by EGR1, and by Hippo signaling [#15, #13, #14, #11, #12]. Loss-of-function studies establish physiological roles in OPC morphogenesis, trophoblast invasion and placentation, angiogenesis during muscle regeneration, and cartilage mechanical homeostasis via mechanically activated ERK1/2 [#28, #18, #29, #20]. A germline CSPG4-A131T missense mutation in iPSC-derived oligodendrocyte precursors causes aberrant protein processing, mislocalization, abnormal morphology, and impaired myelination potential, linking CSPG4 dysfunction to disease [#25].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Established that CSPG4 is not merely a passive matrix component but an adhesion receptor that transduces matrix engagement into survival and motility signaling, defining its mechanistic role in tumor cells.\",\n      \"evidence\": \"Domain-deletion and dominant-negative NG2 mutants, purified collagen VI fragments, RNAi, and xenografts mapping NG2-Col VI binding to PI-3K activation\",\n      \"pmids\": [\"23559515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the membrane-proximal signaling complex linking CSPG4 to PI-3K\", \"Generality beyond sarcoma not established in this study\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved how CSPG4 transcription is restricted to NG2 glia versus pericytes, identifying the cis-regulatory logic that establishes cell-type-specific expression.\",\n      \"evidence\": \"1.45 kb intronic enhancer reporter assays, EGFP transgenic mice, and mutagenesis of SoxE/bHLH binding elements\",\n      \"pmids\": [\"30306660\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the specific SoxE/bHLH family members in vivo\", \"Did not address how pericyte CSPG4 is driven\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended CSPG4's ligand repertoire to perlecan and to FGF1, framing it as a surface reservoir for matrix and growth-factor ligands.\",\n      \"evidence\": \"Immunopurification with perlecan domain-mapping and actin assays; APEX2-FGF1 proximity labeling with mass spectrometry and colocalization\",\n      \"pmids\": [\"29462330\", \"29812912\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"FGF1 storage function not functionally proven downstream\", \"Whether perlecan and FGF1 binding involve overlapping CSPG4 regions unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Solved the structural basis of CSPG4 as the TcdB receptor and validated it in vivo, transforming a cell-surface marker into a defined toxin-host interface with therapeutic relevance.\",\n      \"evidence\": \"Cryo-EM of the TcdB-CSPG4 complex, site-directed mutagenesis disrupting binding, CSPG4-knockout mice, and bezlotoxumab competition\",\n      \"pmids\": [\"34145250\", \"28842504\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the CS contribution to entry kinetics\", \"Relative in vivo contribution versus other TcdB receptors unquantified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined multiple transcriptional inputs (MRTF-SRF, redox-regulated SP-1) that tune CSPG4 abundance in smooth muscle and glia, connecting actin dynamics and cellular redox state to receptor expression.\",\n      \"evidence\": \"MRTF overexpression and SRF silencing with promoter reporters and CCG-1423; Grx2c manipulation with SP-1 redox/DNA-binding analysis across cell, ex vivo, and zebrafish models\",\n      \"pmids\": [\"33727640\", \"34952462\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cross-talk between MRTF-SRF and SP-1 inputs not integrated\", \"Direct redox modification site on SP-1 controlling CSPG4 not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Connected receptor access and expression control in vivo, showing fibroblast-shed CSPG4 and Hippo-dependent transcription govern epithelial susceptibility to TcdB.\",\n      \"evidence\": \"Immunofluorescence of colonic crypt-surface axis; TcdB-resistance selection, CRISPR deletion of Hippo regulators, chemical modulation, and mouse disease protection\",\n      \"pmids\": [\"37747247\", \"36972308\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the protease shedding epithelial CSPG4 not defined\", \"Direct Hippo transcriptional regulators binding the CSPG4 locus not mapped\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed that the chondroitin sulfate modification acts as a binary switch controlling CSPG4 partner choice, with de-CS-modified CSPG4 binding integrin \\u03b1V to drive differentiation versus CS-bearing CSPG4 maintaining stem-like state.\",\n      \"evidence\": \"ChondroitinaseABC and XYLT1/CSPG4 knockdown, co-IP with integrin \\u03b1V, cyclic-RGD inhibition, and proteo-genomics of patient-derived glioma-initiating cells\",\n      \"pmids\": [\"38309500\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzyme/signal controlling CS removal physiologically not identified\", \"Whether this switch operates in non-glioma contexts unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Genetically isolated a specific physiological function of CSPG4, distinguishing OPC morphogenesis from differentiation and myelination.\",\n      \"evidence\": \"cspg4 loss-of-function zebrafish with morphology, differentiation, and myelin sheath quantification\",\n      \"pmids\": [\"39566199\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular effector of morphogenesis downstream of CSPG4 not defined\", \"Mammalian conservation of this restricted phenotype untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Proposed a mechanotransduction mechanism whereby neuronal NLGN3 binds CSPG4 and triggers ADAM10 shedding, altering membrane tension to activate PIEZO1 and maintain undifferentiated, proliferative states.\",\n      \"evidence\": \"Biochemical NLGN3-CSPG4 binding, ADAM10 shedding, PIEZO1 channel and membrane-tension measurements, glioma proliferation assays (preprint)\",\n      \"pmids\": [\"40791371\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not yet peer reviewed\", \"Direct causal chain from shedding to PIEZO1 activation not fully reconstituted\", \"In vivo requirement untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CSPG4's diverse inputs\\u2014CS-state, matrix ligands, growth factors, and mechanical force\\u2014are integrated at the cytoplasmic tail into a unified signaling output remains undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No defined cytoplasmic signaling complex linking CSPG4 to ERK/AKT\", \"No structural model of the full-length receptor with its CS chains\", \"Quantitative hierarchy among transcriptional regulators in any single cell type unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [4, 5, 8]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [5, 6, 8, 19]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 3, 16, 19]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 6, 8, 19]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [15, 13, 14, 11, 12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TcdB\", \"COL6\", \"HSPG2\", \"ITGAV\", \"FGF1\", \"NLGN3\", \"ADAM10\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":8,"faith_pct":87.5}}